Cocrystal Q3 Loss Widens to $3.4M; Going Concern Reiterated With $4.9M Cash
COCP sits 28% above its 52-week low of $0.76 on light trading volume (0.3× avg).
Summary
Cocrystal's Q3 2026 10-Q shows a $3.4M quarterly loss, $4.9M of cash and restricted cash, and a reiterated going-concern warning with less than 12 months of runway. The Phase 1b norovirus study has finished dosing and is moving to topline analysis.
Key Events · Earnings and Guidance · COCP
-
Q3 Loss Widens to $3.4M
Net loss was $3.444M for the three months ended September 30, 2026, versus $2.049M a year earlier; nine-month loss reached $8.907M versus $6.405M.
-
Cash Falls to $4.9M, Runway Under 12 Months
Cash and restricted cash were $4.948M at September 30, 2026, down from $7.100M at December 31, 2025, after $7.152M of operating cash burn. Management states current resources will not fund operations for at least the next 12 months.
-
Going Concern Warning Reiterated
The 10-Q repeats substantial doubt about the ability to continue as a going concern, noting the auditor's explanatory paragraph on the December 31, 2025 financial statements.
-
OPKO Placement Added $5.0M in July
On July 31, 2026 the company sold 5,474,053 shares to OPKO Health at $0.9134 per share for $5.0M gross, a related-party transaction with Dr. Phillip Frost.
Analysis · COCP · Life Sciences
Cocrystal burned $7.2M of operating cash in nine months and ended September with $4.9M in cash and restricted cash, which management says will not fund operations for the next 12 months. The going-concern warning is not new, but the runway is now short enough that another raise is near-certain, and any equity financing at today's price would be heavily dilutive. The one offset is clinical progress: the Phase 1b norovirus challenge study finished dosing in September and is heading into topline analysis, a potential value inflection if the data hold up.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, COCP was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.9M. The 52-week trading range was $0.76 to $2.03. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.